NCT06561516 is a NA clinical trial of Arm I (Red ginseng) in Stomach Cancer, sponsored by Gangnam Severance Hospital.

Who is sponsoring NCT06561516?

NCT06561516 is sponsored by Gangnam Severance Hospital.

What drugs are being tested in NCT06561516?

Interventions in NCT06561516: Arm I (Red ginseng).

What condition does NCT06561516 study?

NCT06561516 studies Stomach Cancer, Pancreatobiliary Cancer, Colorectal Cancer.

Is NCT06561516 still recruiting?

NCT06561516 is currently completed. Last updated 20 August 2024.

Last reviewed 2024-08-20 · How we verify

NCT06561516

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Red Ginseng on Gastrointestinal Symptoms and Microbiota After Surgery for Gastrointestinal Cancer

Completed NA Last updated 20 August 2024

What this trial tests

NA trial testing Arm I (Red ginseng) in Stomach Cancer in 60 participants. Completed in 14 July 2023.

Timeline

14 June 2022

Primary endpoint
14 July 2023

14 July 2023

Quick facts

Lead sponsor	Gangnam Severance Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	60
Start date	14 June 2022
Primary completion	14 July 2023
Estimated completion	14 July 2023
Sites	1 location across South Korea

Drugs / interventions tested

Arm I (Red ginseng)

Conditions studied

Stomach Cancer — all drugs for Stomach Cancer →
Pancreatobiliary Cancer — all drugs for Pancreatobiliary Cancer →
Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

Gangnam Severance Hospital

Who can join

Adults 19 to 79, any sex, with Stomach Cancer or Pancreatobiliary Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

After surgery for gastrointestinal cancer (stomach cancer, pancreaticobiliary cancer, colorectal cancer), many patients experiences various symptoms such as weight loss, diarrhea, constipation and excessive gas due to structural and functional changes in the gastrointestinal tract. These changes are thought to be influenced by alterations in gut microbiota following surgery, but prospective studies are still lacking. It is anticipated that the prebiotic effects of red ginseng may lead to positive changes in total gut bactera after gastrointestinal caner surgery. Through this study, Investigators aim to investigate the impact of red ginseng consumption on gut microbiota composition, gastrointestinal symptoms, and nutritional status improvement following surgery for gastrointestinal cancer.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy.
Godiyal Y, Maheshwari D, Taniguchi H, Zinzuwadia SS, et al · · 2024 · cited 21× · PMID 39690423 · DOI 10.1186/s40779-024-00586-9
Exploring the role of gut microbiota in colorectal liver metastasis through the gut-liver axis.
Liu QL, Zhou H, Wang Z, Chen Y. · · 2025 · cited 1× · PMID 40181829 · DOI 10.3389/fcell.2025.1563184
Effects of red ginseng on gut microbiome in patients after gastrointestinal cancer surgery: A pilot, randomized controlled trial.
Seo Y, Jung JE, Oh S, Kwon IG, et al · · 2026 · PMID 42112126 · DOI 10.1016/j.jgr.2025.100932

Verify or expand the search:

Other recruiting trials for Stomach Cancer

Currently open trials in the same condition.

NCT07504367 — Large Language Models Assist in Tumor MDT · NA · recruiting
NCT07310888 — Robotic Gastrectomy With 5th Arm · NA · recruiting
NCT07070466 — Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA · Phase 2 · recruiting
NCT06028737 — Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer · Phase 2, PHASE3 · recruiting
NCT06263088 — EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastroint · NA · recruiting

Other Gangnam Severance Hospital trials

Trials by the same sponsor.

NCT07505628 — AI-based Rehabilitation for Hip and Knee Surgery Patients · NA · not yet recruiting
NCT07311122 — Endocrine Therapy Base on 21-gene RS · not yet recruiting
NCT07011823 — Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC · Phase 2 · not yet recruiting
NCT07211451 — Axillary Nodal Burden in HER2+ and TNBC · completed
NCT06839716 — Comparison of Ropivacaine-Poloxamer 407 Hydrogel and TAP Block for Postoperative Pain Management in Laparoscopic/Robotic · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06561516 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gangnam Severance Hospital
Last refreshed: 20 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06561516.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing